A prospective monitoring study for those individuals treated with Paxlovid
The purpose of this study is to understand the epidemiology and pathophysiology of
Paxlovid rebound in patients with acute Covid-19 infection who have been prescribed the
Paxlovid per standard of care.
The study will be a collaborative effort between Scripps and eMed, digitally recruiting
800 participants who have tested positive for Covid-19 and have agreed to be prescribed
Paxlovid on the eMed platform.
The vision of the study is to understand Paxlovid rebound and ultimately inform
management of acute Covid-19 infection.
Inclusion Criteria:
- Age > 18
- Covid positive
- Qualified for Paxlovid prescription (treatment decision already made prior to
enrollment)
Exclusion Criteria:
- Non-english speaking
- Resides outside of the United States
Scripps Research Institute
San Diego, California, United States
Jay Pandit, MD, Principal Investigator
Scripps Research Institute